Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response.

导出 OA

翻译打印收藏纠错

作者： Irene,Fischetti ^[1] ; Laura,Botti ^[1] ; Roberta,Sulsenti ^[1] ; Valeria,Cancila ^[2] ; Claudia,Enriquez ^[1] ; Renata,Ferri ^[1] ; Marco,Bregni ^[3] ; Filippo,Crivelli ^[4] ; Claudio,Tripodo ^[2] ; Mario P,Colombo ^[1] ; Elena,Jachetti ^[1]

作者单位： Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. ^[1] Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Italy. ^[2] ASST Valle Olona, Busto Arsizio, Italy. ^[3] Anatomia Patologica, ASST Valle Olona, Busto Arsizio, Italy. ^[4]

关键词 castration resistance epigenetic regulation mouse models prostate cancer tumor immunology

DOI 10.2217/epi-2023-0374

PMID 38530086

发布时间 2024-06-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Epigenomics

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response.

Epigenomics

相似文献

Epigenomics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response.

Epigenomics

相似文献

Epigenomics

相关期刊

检索历史清除